Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41467-020-20602-5 http://scihub22266oqcxt.onion/10.1038/s41467-020-20602-5 33436577!7803729!33436577     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Commun 2021 ; 12 (1): 288 Nephropedia Template TP {{tp|p=33436577|t=2021. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein |pdf=|usr=}}{{33436577}} gab.com Text A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein JO: Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33436577 #FOAvip Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19. Twit Text FOAVip A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein ????Nat Commun http://www.kidney.de/pget.php?&tw=1&pmid=33436577 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33436577 #FOAvip English Wikipedia <ref>{{Cite pmid|33436577}}</ref> A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein #MMPMID33436577 Kim C; Ryu DK; Lee J; Kim YI; Seo JM; Kim YG; Jeong JH; Kim M; Kim JI; Kim P; Bae JS; Shim EY; Lee MS; Kim MS; Noh H; Park GS; Park JS; Son D; An Y; Lee JN; Kwon KS; Lee JY; Lee H; Yang JS; Kim KC; Kim SS; Woo HM; Kim JW; Park MS; Yu KM; Kim SM; Kim EH; Park SJ; Jeong ST; Yu CH; Song Y; Gu SH; Oh H; Koo BS; Hong JJ; Ryu CM; Park WB; Oh MD; Choi YK; Lee SY Nat Commun 2021[Jan]; 12 (1): 288 PMID33436577show ga Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal antibodies (mAb) targeting the receptor binding domain (RBD) of the viral spike protein via antibody library constructed from peripheral blood mononuclear cells of a convalescent patient. The CT-P59 mAb potently neutralizes SARS-CoV-2 isolates including the D614G variant without antibody-dependent enhancement effect. Complex crystal structure of CT-P59 Fab/RBD shows that CT-P59 blocks interaction regions of RBD for angiotensin converting enzyme 2 (ACE2) receptor with an orientation that is notably different from previously reported RBD-targeting mAbs. Furthermore, therapeutic effects of CT-P59 are evaluated in three animal models (ferret, hamster, and rhesus monkey), demonstrating a substantial reduction in viral titer along with alleviation of clinical symptoms. Therefore, CT-P59 may be a promising therapeutic candidate for COVID-19. |*COVID-19 Drug Treatment[MESH] |Angiotensin-Converting Enzyme 2/chemistry[MESH] |Animals[MESH] |Antibodies, Monoclonal/immunology[MESH] |Antibodies, Neutralizing/chemistry/immunology/*pharmacology[MESH] |Antibodies, Viral/immunology[MESH] |Chlorocebus aethiops[MESH] |Disease Models, Animal[MESH] |Female[MESH] |Ferrets[MESH] |Humans[MESH] |Leukocytes, Mononuclear[MESH] |Macaca mulatta[MESH] |Male[MESH] |Mesocricetus[MESH] |Models, Molecular[MESH] |Protein Binding/*drug effects[MESH] |Protein Conformation[MESH] |SARS-CoV-2/*drug effects[MESH] |Spike Glycoprotein, Coronavirus/chemistry/*drug effects[MESH]A therapeutic neutralizing antibody targeting receptor binding domain (epmc).pdf DeepDyve Pubget Overpricing